DS-1 (drug)
DS-1 is a drug from the imidazopyridine family, which is the first drug developed that acts as a GABAA receptor positive allosteric modulator (PAM) selective for the α4β3δ subtype, which is not targeted by other GABAA receptor PAMs such as the benzodiazepines or other nonbenzodiazepine drugs. Novel selective drugs such as DS-1 should prove useful in the study of this receptor subtype.[1]
Identifiers | |
---|---|
IUPAC name
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.209.966 |
Chemical and physical data | |
Formula | C18H10Br2ClN3OS |
Molar mass | 511.617 g/mol g·mol−1 |
3D model (JSmol) | |
SMILES
| |
(verify) |
References
- Wafford, KA; Van Niel, MB; Ma, QP; Horridge, E; Herd, MB; Peden, DR; Belelli, D; Lambert, JJ (2009). "Novel compounds selectively enhance delta subunit containing GABA a receptors and increase tonic currents in thalamus". Neuropharmacology. 56 (1): 182–9. doi:10.1016/j.neuropharm.2008.08.004. PMID 18762200.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.